Genome Sequencing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Nucleotide Sequenced (DNA v/s RNA), By Technique (Next Generation Sequencing, PCR, Microarray Technology, Others), By Application (Diagnostics, Drug Discovery & Development, Precision Medicine, Others), By End User (Academic & Research Institutions, Pharmaceutical & Biotechnology Companies, Hospitals & Clinics, Others), By Region & Competition, 2021-2031F
The global genome sequencing market is poised for significant expansion, projected to reach USD 71.54 Billion by 2031 from USD 20.55 Billion in 2025, demonstrating a 23.11% CAGR. This growth is primarily fueled by decreasing sequencing costs and the increasing integration of genomic data into precision medicine for personalized treatments. The ongoing stewardship of millions of genomes by organizations like the Global Alliance for Genomics and Health further highlights the growing adoption and utility of sequencing technologies in global health.
However, this robust growth is tempered by substantial challenges related to data privacy and the ethical handling of sensitive genetic information. The need for secure storage and strict regulatory compliance for the vast amounts of genomic data introduces operational complexities, potentially hindering the smooth implementation of sequencing workflows in clinical settings.
Market Driver
The genome sequencing market is primarily driven by the increasing global incidence of cancer and rare genetic disorders, which demand advanced diagnostic and therapeutic approaches. Clinicians' growing reliance on genomic profiles for precision medicine in oncology and rare disease management has significantly amplified the need for sequencing, evidenced by projections such as over 2,041,000 new cancer cases in the United States in 2025. This substantial disease burden highlights the crucial requirement for scalable sequencing solutions to facilitate personalized treatment and enhance patient outcomes worldwide.
Concurrently, the ongoing reduction in sequencing costs and enhanced accessibility are making genomic data more widely available, fostering population-scale biobanking and expanded clinical integration. Technological advancements have lowered financial hurdles, enabling large-scale research initiatives, as demonstrated by the successful analysis of nearly half a million whole genomes from the UK Biobank, while government investments, such as the UK's ?520 million allocation for life sciences manufacturing, further bolster accessible sequencing infrastructure.
Market Challenge
A significant challenge impeding the global genome sequencing market's growth is the critical need for robust data privacy management and ethical handling of sensitive genetic information. With escalating sequencing volumes, the potential for data breaches and unauthorized access to personal genomic data increases, demanding stringent security measures that complicate data sharing and storage. Organizations must navigate complex international regulations, leading to operational delays and higher compliance costs, which in turn hinder the smooth incorporation of sequencing into clinical workflows.
These privacy and security concerns are substantial, with 41% of life science professionals identifying them as a major barrier to adopting digital laboratory technologies in 2024. This apprehension underscores the difficulty market participants face in balancing the clinical utility of genomic data with the essential requirement to protect patient confidentiality, ultimately diverting resources from innovation and slowing market expansion.
Market Trends
The integration of Artificial Intelligence and Machine Learning for automated genomic data analysis is profoundly transforming the market by addressing the critical bottleneck of data interpretation. As sequencing throughput increases, the overwhelming volume of raw data necessitates algorithmic solutions for rapid variant calling and clinical annotation, significantly reducing turnaround times for diagnostics and enabling near real-time applications in critical care. For example, AI integration in Illumina's DRAGEN v4.4 software enhanced structural variant calling accuracy by 30%, improving the clinical utility of genomic results.
Concurrently, the accelerated adoption of third-generation long-read sequencing technologies is expanding the market by overcoming the limitations of traditional short-read platforms. These technologies allow for sequencing long DNA stretches without fragmentation, enabling precise detection of large structural variants and complex repetitive regions previously missed. This technical advantage is fueling strong commercial demand across research and clinical sectors seeking comprehensive genomic maps, evidenced by Oxford Nanopore Technologies' 11% revenue increase, reflecting global demand for its nanopore-based long-read sequencing solutions.
Key Market Players
In this report, the Global Genome Sequencing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in the Global Genome Sequencing Market.
Available Customizations:
Global Genome Sequencing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
However, this robust growth is tempered by substantial challenges related to data privacy and the ethical handling of sensitive genetic information. The need for secure storage and strict regulatory compliance for the vast amounts of genomic data introduces operational complexities, potentially hindering the smooth implementation of sequencing workflows in clinical settings.
Market Driver
The genome sequencing market is primarily driven by the increasing global incidence of cancer and rare genetic disorders, which demand advanced diagnostic and therapeutic approaches. Clinicians' growing reliance on genomic profiles for precision medicine in oncology and rare disease management has significantly amplified the need for sequencing, evidenced by projections such as over 2,041,000 new cancer cases in the United States in 2025. This substantial disease burden highlights the crucial requirement for scalable sequencing solutions to facilitate personalized treatment and enhance patient outcomes worldwide.
Concurrently, the ongoing reduction in sequencing costs and enhanced accessibility are making genomic data more widely available, fostering population-scale biobanking and expanded clinical integration. Technological advancements have lowered financial hurdles, enabling large-scale research initiatives, as demonstrated by the successful analysis of nearly half a million whole genomes from the UK Biobank, while government investments, such as the UK's ?520 million allocation for life sciences manufacturing, further bolster accessible sequencing infrastructure.
Market Challenge
A significant challenge impeding the global genome sequencing market's growth is the critical need for robust data privacy management and ethical handling of sensitive genetic information. With escalating sequencing volumes, the potential for data breaches and unauthorized access to personal genomic data increases, demanding stringent security measures that complicate data sharing and storage. Organizations must navigate complex international regulations, leading to operational delays and higher compliance costs, which in turn hinder the smooth incorporation of sequencing into clinical workflows.
These privacy and security concerns are substantial, with 41% of life science professionals identifying them as a major barrier to adopting digital laboratory technologies in 2024. This apprehension underscores the difficulty market participants face in balancing the clinical utility of genomic data with the essential requirement to protect patient confidentiality, ultimately diverting resources from innovation and slowing market expansion.
Market Trends
The integration of Artificial Intelligence and Machine Learning for automated genomic data analysis is profoundly transforming the market by addressing the critical bottleneck of data interpretation. As sequencing throughput increases, the overwhelming volume of raw data necessitates algorithmic solutions for rapid variant calling and clinical annotation, significantly reducing turnaround times for diagnostics and enabling near real-time applications in critical care. For example, AI integration in Illumina's DRAGEN v4.4 software enhanced structural variant calling accuracy by 30%, improving the clinical utility of genomic results.
Concurrently, the accelerated adoption of third-generation long-read sequencing technologies is expanding the market by overcoming the limitations of traditional short-read platforms. These technologies allow for sequencing long DNA stretches without fragmentation, enabling precise detection of large structural variants and complex repetitive regions previously missed. This technical advantage is fueling strong commercial demand across research and clinical sectors seeking comprehensive genomic maps, evidenced by Oxford Nanopore Technologies' 11% revenue increase, reflecting global demand for its nanopore-based long-read sequencing solutions.
Key Market Players
- Illumina, Inc
- Thermo Fisher Scientific Inc
- F. Hoffmann-La Roche Ltd
- Oxford Nanopore Technologies plc
- BGI Genomics Co., Ltd
- QIAGEN N.V
- Pacific Biosciences of California, Inc
- PerkinElmer, Inc
- Agilent Technologies, Inc
- Macrogen, Inc
In this report, the Global Genome Sequencing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
- Genome Sequencing Market, By Nucleotide Sequenced
- DNA
- RNA
- Genome Sequencing Market, By Technique
- Next Generation Sequencing
- PCR
- Microarray Technology
- Others
- Genome Sequencing Market, By Application
- Diagnostics
- Drug Discovery & Development
- Precision Medicine
- Others
- Genome Sequencing Market, By End User
- Academic & Research Institutions
- Pharmaceutical & Biotechnology Companies
- Hospitals & Clinics
- Others
- Genome Sequencing Market, By Region
- North America
- United States
- Canada
- Mexico
- Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Company Profiles: Detailed analysis of the major companies present in the Global Genome Sequencing Market.
Available Customizations:
Global Genome Sequencing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. PRODUCT OVERVIEW
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL GENOME SEQUENCING MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Nucleotide Sequenced (DNA v/s RNA)
5.2.2. By Technique (Next Generation Sequencing, PCR, Microarray Technology, Others)
5.2.3. By Application (Diagnostics, Drug Discovery & Development, Precision Medicine, Others)
5.2.4. By End User (Academic & Research Institutions, Pharmaceutical & Biotechnology Companies, Hospitals & Clinics, Others)
5.2.5. By Region
5.2.6. By Company (2025)
5.3. Market Map
6. NORTH AMERICA GENOME SEQUENCING MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Nucleotide Sequenced
6.2.2. By Technique
6.2.3. By Application
6.2.4. By End User
6.2.5. By Country
6.3. North America: Country Analysis
6.3.1. United States Genome Sequencing Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Nucleotide Sequenced
6.3.1.2.2. By Technique
6.3.1.2.3. By Application
6.3.1.2.4. By End User
6.3.2. Canada Genome Sequencing Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Nucleotide Sequenced
6.3.2.2.2. By Technique
6.3.2.2.3. By Application
6.3.2.2.4. By End User
6.3.3. Mexico Genome Sequencing Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Nucleotide Sequenced
6.3.3.2.2. By Technique
6.3.3.2.3. By Application
6.3.3.2.4. By End User
7. EUROPE GENOME SEQUENCING MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Nucleotide Sequenced
7.2.2. By Technique
7.2.3. By Application
7.2.4. By End User
7.2.5. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Genome Sequencing Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Nucleotide Sequenced
7.3.1.2.2. By Technique
7.3.1.2.3. By Application
7.3.1.2.4. By End User
7.3.2. France Genome Sequencing Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Nucleotide Sequenced
7.3.2.2.2. By Technique
7.3.2.2.3. By Application
7.3.2.2.4. By End User
7.3.3. United Kingdom Genome Sequencing Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Nucleotide Sequenced
7.3.3.2.2. By Technique
7.3.3.2.3. By Application
7.3.3.2.4. By End User
7.3.4. Italy Genome Sequencing Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Nucleotide Sequenced
7.3.4.2.2. By Technique
7.3.4.2.3. By Application
7.3.4.2.4. By End User
7.3.5. Spain Genome Sequencing Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Nucleotide Sequenced
7.3.5.2.2. By Technique
7.3.5.2.3. By Application
7.3.5.2.4. By End User
8. ASIA PACIFIC GENOME SEQUENCING MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Nucleotide Sequenced
8.2.2. By Technique
8.2.3. By Application
8.2.4. By End User
8.2.5. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Genome Sequencing Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Nucleotide Sequenced
8.3.1.2.2. By Technique
8.3.1.2.3. By Application
8.3.1.2.4. By End User
8.3.2. India Genome Sequencing Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Nucleotide Sequenced
8.3.2.2.2. By Technique
8.3.2.2.3. By Application
8.3.2.2.4. By End User
8.3.3. Japan Genome Sequencing Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Nucleotide Sequenced
8.3.3.2.2. By Technique
8.3.3.2.3. By Application
8.3.3.2.4. By End User
8.3.4. South Korea Genome Sequencing Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Nucleotide Sequenced
8.3.4.2.2. By Technique
8.3.4.2.3. By Application
8.3.4.2.4. By End User
8.3.5. Australia Genome Sequencing Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Nucleotide Sequenced
8.3.5.2.2. By Technique
8.3.5.2.3. By Application
8.3.5.2.4. By End User
9. MIDDLE EAST & AFRICA GENOME SEQUENCING MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Nucleotide Sequenced
9.2.2. By Technique
9.2.3. By Application
9.2.4. By End User
9.2.5. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Genome Sequencing Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Nucleotide Sequenced
9.3.1.2.2. By Technique
9.3.1.2.3. By Application
9.3.1.2.4. By End User
9.3.2. UAE Genome Sequencing Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Nucleotide Sequenced
9.3.2.2.2. By Technique
9.3.2.2.3. By Application
9.3.2.2.4. By End User
9.3.3. South Africa Genome Sequencing Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Nucleotide Sequenced
9.3.3.2.2. By Technique
9.3.3.2.3. By Application
9.3.3.2.4. By End User
10. SOUTH AMERICA GENOME SEQUENCING MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Nucleotide Sequenced
10.2.2. By Technique
10.2.3. By Application
10.2.4. By End User
10.2.5. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Genome Sequencing Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Nucleotide Sequenced
10.3.1.2.2. By Technique
10.3.1.2.3. By Application
10.3.1.2.4. By End User
10.3.2. Colombia Genome Sequencing Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Nucleotide Sequenced
10.3.2.2.2. By Technique
10.3.2.2.3. By Application
10.3.2.2.4. By End User
10.3.3. Argentina Genome Sequencing Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Nucleotide Sequenced
10.3.3.2.2. By Technique
10.3.3.2.3. By Application
10.3.3.2.4. By End User
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. GLOBAL GENOME SEQUENCING MARKET: SWOT ANALYSIS
14. PORTER'S FIVE FORCES ANALYSIS
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. COMPETITIVE LANDSCAPE
15.1. Illumina, Inc
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. Thermo Fisher Scientific Inc
15.3. F. Hoffmann-La Roche Ltd
15.4. Oxford Nanopore Technologies plc
15.5. BGI Genomics Co., Ltd
15.6. QIAGEN N.V
15.7. Pacific Biosciences of California, Inc
15.8. PerkinElmer, Inc
15.9. Agilent Technologies, Inc
15.10. Macrogen, Inc
16. STRATEGIC RECOMMENDATIONS
17. ABOUT US & DISCLAIMER
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL GENOME SEQUENCING MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Nucleotide Sequenced (DNA v/s RNA)
5.2.2. By Technique (Next Generation Sequencing, PCR, Microarray Technology, Others)
5.2.3. By Application (Diagnostics, Drug Discovery & Development, Precision Medicine, Others)
5.2.4. By End User (Academic & Research Institutions, Pharmaceutical & Biotechnology Companies, Hospitals & Clinics, Others)
5.2.5. By Region
5.2.6. By Company (2025)
5.3. Market Map
6. NORTH AMERICA GENOME SEQUENCING MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Nucleotide Sequenced
6.2.2. By Technique
6.2.3. By Application
6.2.4. By End User
6.2.5. By Country
6.3. North America: Country Analysis
6.3.1. United States Genome Sequencing Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Nucleotide Sequenced
6.3.1.2.2. By Technique
6.3.1.2.3. By Application
6.3.1.2.4. By End User
6.3.2. Canada Genome Sequencing Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Nucleotide Sequenced
6.3.2.2.2. By Technique
6.3.2.2.3. By Application
6.3.2.2.4. By End User
6.3.3. Mexico Genome Sequencing Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Nucleotide Sequenced
6.3.3.2.2. By Technique
6.3.3.2.3. By Application
6.3.3.2.4. By End User
7. EUROPE GENOME SEQUENCING MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Nucleotide Sequenced
7.2.2. By Technique
7.2.3. By Application
7.2.4. By End User
7.2.5. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Genome Sequencing Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Nucleotide Sequenced
7.3.1.2.2. By Technique
7.3.1.2.3. By Application
7.3.1.2.4. By End User
7.3.2. France Genome Sequencing Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Nucleotide Sequenced
7.3.2.2.2. By Technique
7.3.2.2.3. By Application
7.3.2.2.4. By End User
7.3.3. United Kingdom Genome Sequencing Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Nucleotide Sequenced
7.3.3.2.2. By Technique
7.3.3.2.3. By Application
7.3.3.2.4. By End User
7.3.4. Italy Genome Sequencing Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Nucleotide Sequenced
7.3.4.2.2. By Technique
7.3.4.2.3. By Application
7.3.4.2.4. By End User
7.3.5. Spain Genome Sequencing Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Nucleotide Sequenced
7.3.5.2.2. By Technique
7.3.5.2.3. By Application
7.3.5.2.4. By End User
8. ASIA PACIFIC GENOME SEQUENCING MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Nucleotide Sequenced
8.2.2. By Technique
8.2.3. By Application
8.2.4. By End User
8.2.5. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Genome Sequencing Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Nucleotide Sequenced
8.3.1.2.2. By Technique
8.3.1.2.3. By Application
8.3.1.2.4. By End User
8.3.2. India Genome Sequencing Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Nucleotide Sequenced
8.3.2.2.2. By Technique
8.3.2.2.3. By Application
8.3.2.2.4. By End User
8.3.3. Japan Genome Sequencing Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Nucleotide Sequenced
8.3.3.2.2. By Technique
8.3.3.2.3. By Application
8.3.3.2.4. By End User
8.3.4. South Korea Genome Sequencing Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Nucleotide Sequenced
8.3.4.2.2. By Technique
8.3.4.2.3. By Application
8.3.4.2.4. By End User
8.3.5. Australia Genome Sequencing Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Nucleotide Sequenced
8.3.5.2.2. By Technique
8.3.5.2.3. By Application
8.3.5.2.4. By End User
9. MIDDLE EAST & AFRICA GENOME SEQUENCING MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Nucleotide Sequenced
9.2.2. By Technique
9.2.3. By Application
9.2.4. By End User
9.2.5. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Genome Sequencing Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Nucleotide Sequenced
9.3.1.2.2. By Technique
9.3.1.2.3. By Application
9.3.1.2.4. By End User
9.3.2. UAE Genome Sequencing Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Nucleotide Sequenced
9.3.2.2.2. By Technique
9.3.2.2.3. By Application
9.3.2.2.4. By End User
9.3.3. South Africa Genome Sequencing Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Nucleotide Sequenced
9.3.3.2.2. By Technique
9.3.3.2.3. By Application
9.3.3.2.4. By End User
10. SOUTH AMERICA GENOME SEQUENCING MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Nucleotide Sequenced
10.2.2. By Technique
10.2.3. By Application
10.2.4. By End User
10.2.5. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Genome Sequencing Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Nucleotide Sequenced
10.3.1.2.2. By Technique
10.3.1.2.3. By Application
10.3.1.2.4. By End User
10.3.2. Colombia Genome Sequencing Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Nucleotide Sequenced
10.3.2.2.2. By Technique
10.3.2.2.3. By Application
10.3.2.2.4. By End User
10.3.3. Argentina Genome Sequencing Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Nucleotide Sequenced
10.3.3.2.2. By Technique
10.3.3.2.3. By Application
10.3.3.2.4. By End User
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. GLOBAL GENOME SEQUENCING MARKET: SWOT ANALYSIS
14. PORTER'S FIVE FORCES ANALYSIS
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. COMPETITIVE LANDSCAPE
15.1. Illumina, Inc
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. Thermo Fisher Scientific Inc
15.3. F. Hoffmann-La Roche Ltd
15.4. Oxford Nanopore Technologies plc
15.5. BGI Genomics Co., Ltd
15.6. QIAGEN N.V
15.7. Pacific Biosciences of California, Inc
15.8. PerkinElmer, Inc
15.9. Agilent Technologies, Inc
15.10. Macrogen, Inc
16. STRATEGIC RECOMMENDATIONS
17. ABOUT US & DISCLAIMER
